Around 10 million people in the UK suffer from seasonal allergies, and the number of people with hay fever symptoms is rising. According to a poll by Allergy UK, 37% of people have reported developing symptoms for the first time in the past five years.

Dr. Reddy’s is one of the largest producers of fexofenadine hydrochloride (the active pharmaceutical ingredient in Histallay), the most dispensed antihistamine in the UK.

Previously classified as a Prescription Only Medicine (POM), Dr Reddy’s Fexofenadine 120 mg is now available as Histallay, meaning people with allergic seasonal rhinitis have direct access to the product via retail outlets in the UK.

Histallay is Dr Reddy’s first general sale product in the UK market.

Kristine Oberte, Country Head UK for Dr Reddy’s Laboratories, says: “Our expertise in the allergy sector has already allowed us to become a leader in the UK’s prescription fexofenadine market. By making Histallay available over the counter, we enable allergy sufferers to get faster access to treatment and better control over their symptoms since early treatment is key.”

Dr Reddy’s Laboratories is investing in a media and advertising plan to support pharmacies and supermarkets and drive consumer demand for Histallay.

On average, a pack of 10 tablets of Histallay retails at £4.50, and 30 tablets retails at £11.00.